Trading of Akari Therapeutics was halted at 01:51 PM EST due to "LULD Pause". Akari Therapeutics (AKTX) Institutional Ownership $13.34 +8.20 (+159.53%) As of 02:46 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Akari Therapeutics (NASDAQ:AKTX)CurrentInstitutional OwnershipPercentage5.06%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$63.97MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$2.55M Get AKTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Akari Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data AKTX Institutional Buying and Selling by Quarter Akari Therapeutics Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/18/2026 Armistice Capital LLC2,723,966$787K0.0%N/A5.950% 11/12/2025 Cresset Asset Management LLC822,468$831K0.0%+4,368.0%2.522% 11/6/2025 Omnia Family Wealth LLC28,440$29K0.0%-54.6%0.087% 7/28/2025 Omnia Family Wealth LLC62,690$73K0.0%-28.5%0.195% 2/5/2024Omnia Family Wealth LLC87,628$273K0.1%+48.2%1.551% 11/15/2023Sabby Management LLC178,091$703K0.5%-97.6%3.152% 11/14/2022Armistice Capital LLC4,290,000$2.70M0.0%N/A5.762% 10/27/2022Omnia Family Wealth LLC782,372$493K0.4%+3.2%1.051% 5/6/2022Omnia Family Wealth LLC758,144$910K0.6%+13.7%1.277% 4/13/2022Hikari Power Ltd130,821$157K0.0%+45.7%0.220% AKTX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AKTX shares? During the previous two years, the following institutional investors and hedge funds held shares of Akari Therapeutics shares: Cresset Asset Management LLC ($831K), and Armistice Capital LLC ($787K), Omnia Family Wealth LLC ($29K).Learn more on Akari Therapeutics' institutional investors. What percentage of Akari Therapeutics' stock is owned by institutional investors? 5.06% of Akari Therapeutics' stock is owned by institutional investors. Learn more on AKTX's institutional investor holdings. Which institutional investors have been buying Akari Therapeutics' stock? The following institutional investors have purchased Akari Therapeutics' stock in the last 24 months: Armistice Capital LLC ($2.72M), and Cresset Asset Management LLC ($804.06K). How much institutional buying is happening at Akari Therapeutics? Institutional investors have bought a total of 3,528,026 shares in the last 24 months. This purchase volume represents approximately $63.97M in transactions. Which of Akari Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Akari Therapeutics stock in the last 24 months: Omnia Family Wealth LLC ($59.19K). How much institutional selling is happening at Akari Therapeutics? Institutional investors have sold a total of 59,188 shares in the last 24 months. This volume of shares sold represents approximately $2.55M in transactions. Related Companies TherapeuticsMD Institutional Ownership AEON Biopharma Institutional Ownership Celularity Institutional Ownership VYNE Therapeutics Institutional Ownership Exicure Institutional Ownership Traws Pharma Institutional Ownership Quince Therapeutics Institutional Ownership Pasithea Therapeutics Institutional Ownership Longeveron Institutional Ownership Quantum Biopharma Institutional Ownership This page (NASDAQ:AKTX) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
